A dual antagonist of 5-HT2A and σ2 receptors
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

CYR-101

Item No. 29773

Technical Information
Formal Name
2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]-4-piperidinyl]methyl]-2,3-dihydro-1H-isoindol-1-one
CAS Number
359625-79-9
Molecular Formula
C22H23FN2O2
Formula Weight
Purity
≥95%
A solid
DMF: 10mg/mLDMF:PBS (pH 7.2) (1:3): 0.25mg/mLDMSO: 5mg/mLEthanol: 3mg/mL
λmax
229, 244 nm
SMILES
O=C1N(CC2CCN(CC(C3=CC=C(F)C=C3)=O)CC2)CC4=CC=CC=C41
InChi Code
InChI=1S/C22H23FN2O2/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27/h1-8,16H,9-15H2
InChi Key
RNRYULFRLCBRQS-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    CYR-101 is a dual antagonist of the serotonin (5-HT) receptor subtype 5-HT2A and sigma-2 (σ2) receptors (Kis = 7.53 and 8.19 nM, respectively).1

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Davidson, M., Saoud, J., Staner, C., et al. Efficacy and safety of MIN-101: A 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am. J. Psychiatry 174(12), 1195-1202 (2017).